Status:
TERMINATED
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Lead Sponsor:
Gilead Sciences
Conditions:
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy of the combination entospletinib and idelalisib in participants with relapsed or refractory hematologic malignancies. Participants will be enrolled who have one o...
Eligibility Criteria
Inclusion
- Key
- Diagnosis of B-cell indolent non-Hodgkin lymphoma (iNHL),diffuse large B-cell lymphoma (DLBCL),mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) as documented by medical records and with histology based on criteria established by the World Health Organization
- For institutions that have Phase 3 or Phase 4 protocols studying idelalisib (Zydelig®; GS-1101); individuals with malignancies being studied in these protocols must have failed screening and be registered as a screen failure in the respective idelalisib protocol
- Prior treatment for lymphoid malignancy
- Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy
- Discontinuation of all therapy for the treatment of cancer ≥ 3 weeks before the start of study drug
- All acute toxic effects of any prior antitumor therapy resolved to Grade ≤ 1 before the start of study drug
- Karnofsky performance status of ≥ 60
- Life expectancy of at least 3 months
- Key
Exclusion
- Known histological transformation from iNHL or CLL to an aggressive form of NHL (ie, Richter transformation)
- Known active central nervous system or leptomeningeal lymphoma
- Presence of known intermediate- or high-grade myelodysplastic syndrome
- Current therapy with agents that reduce gastric acidity, including but not limited to antacids, H2 inhibitors, and proton pump inhibitors
- Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug
- Ongoing liver injury
- Ongoing or recent hepatic encephalopathy
- Ongoing drug-induced pneumonitis
- Ongoing inflammatory bowel disease
- Ongoing alcohol or drug addiction
- Pregnancy or breastfeeding
- History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
- Ongoing immunosuppressive therapy
- Concurrent participation in an investigational drug trial with therapeutic intent
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
June 20 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2016
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT01796470
Start Date
June 20 2013
End Date
December 22 2016
Last Update
June 2 2020
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
2
Pacific Shores Medical Group
Long Beach, California, United States, 90813
3
Ventura County Hematology Oncology Specialists
Oxnard, California, United States, 93030
4
Cancer Center of Santa Barbara
Santa Barbara, California, United States, 93105